共 50 条
- [31] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label studyCANCER RESEARCH, 2021, 81 (04)Hamilton, ErikaShapiro, Charles L.Petrylak, DanielBoni, ValentinaMartin, MiguelDel Conte, GianlucaCortes, JavierAgarwal, LailaArkenau, Hendrik-TobiasTan, Antoinette R.Debruyne, PhilipMinchom, AnnaRutten, AnnemieValdes-Albini, FrancesYu, Evan Y.Augustine, BincyD'Amelio, Anthony, Jr.Barrios, DanielHurvitz, Sara A.
- [32] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (vol 20, pg 816, 2019)LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293Tamura, K.Tsurutani, J.Takahashi, S.
- [33] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancerMOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)Chang, Dwan-YingLin, Chia-ChiChen, Tom Wei-WuLin, Ching-HungLee, Jih-HsiangChao, Ta-ChungLiu, Chun-YuAchiwa, IsseiKamiyama, EmiOkuda, YasuyukiLee, CalebChao, Yee
- [34] Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignanciesCANCER MEDICINE, 2024, 13 (14):DiNardo, Courtney D.Olin, RebeccaWang, Eunice S.Skikne, BarryRosenthal, JosephKumar, PrasannaSumi, HiroyukiHizukuri, YoshiyukiHong, YingPatel, ParulSeki, TakahikoDuan, TaoLesegretain, ArnaudAndreeff, Michael
- [35] A PHASE 1 DOSE ESCALATION STUDY OF PRS-343, A HER2/4-1BB BISPECIFIC MOLECULE, IN PATIENTS WITH HER2-POSITIVE MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A1 - A2Piha-Paul, SarinaBendell, JohannaTolcher, AnthonyHurvitz, SaraPatnaik, AmitaShroff, RachnaPohlmann, PaulaZettl, MarkusHahn, NoahKrishnamurthy, AnuradhaDuerr, ManuelaMei, JianAviano, KaytiYusuf, RushdiaMatis, LouisOlwill, ShaneBruns, IngmarKu, Geoffrey
- [36] A phase 1 dose escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignanciesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Hegde, AparnaJayaprakash, PriyamvadaSumner, ElizabethDi NguyenZain, HiraPiha-Paul, SarinaKarp, DanielRodon, JordiPant, ShubhamFu, SiqingDumbrava, EcaterinaYap, TimothySubbiah, VivekBhosale, PriyaHiggins, JackWilliams, Eric T.Wilson, Thomas F.Meric-Bernstam, FundaCurran, MichaelHong, David
- [37] Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 b/g alone or in combination with pembrolizumab: Initial results from dose escalationJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Starodub, AlexanderPowderly, John D.Kim, Sung-BaeDavar, DiwakarHill, Andrew GrahamYeku, Oladapo O.Gabrail, Nashat Y.Krapp, ChristianPihl, SusanneZhang, YingSlavsky, SibelCastro, Davis Y. TorrejonUyei, AnneSingel, Stina MuiKwatra, Vineet
- [39] Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Hamilton, Erika PaigeBarve, Minal A.Bardia, AdityaBeeram, MuralidharBendell, Johanna C.Mosher, RebeccaHailman, EricBergstrom, Donald AlanBurris, Howard A.Soliman, Hatem Hussein
- [40] A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Baselga, JoseTamura, KenjiYamashita, ToshinariModi, ShanuTokunaga, ErikoIto, YoshinoriIwata, HirojiCharif, MahmoudLee, Caleb C.Sugihara, MasahiroJikoh, TakahiroAndre, Fabrice